The Genentech option exercise is the key catalyst—it validates Recursion's platform and de-risks the collaboration model. Monitor for the FDA registrational path update for REC-4881 in 2H26 and the REC-7735 Phase 1/2 initiation. The revenue miss is largely a timing artifact of collaboration milestones, not a business deterioration signal.
Price Chart
Executive Summary
Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 consensus), a miss on both top and bottom lines. The headline financials are weak, but the stock is likely to move on the operational catalyst: Genentech exercised the first Validated Target Option under the neuroscience collaboration, advancing a novel target into early discovery—a key platform validation. The company also lowered 2026 cash operating expense guidance to <$375M (from <$390M), extending runway into early 2028 without additional financing.
Key Financial Metrics
Key Facts
- Revenue of $7.7M missed $12.0M consensus and declined 60% YoY from $19.2M
- GAAP EPS of -$0.25 missed consensus of -$0.23
- Genentech exercised first Validated Target Option under neuroscience collaboration, advancing a novel target into early discovery
- 2026 cash operating expense guidance lowered to <$375M from <$390M, extending cash runway into early 2028
- Cash position $556.8M as of June 30, 2026, down from $753.9M at Dec 31, 2025
- Net loss improved to -$131.0M from -$171.9M YoY, driven by lower R&D and G&A expenses
Financial Impact
Revenue miss of $4.3M (36% below consensus); EPS miss of $0.02 (6.8% below consensus); cash burn of $105.9M in Q2 2026
Risk Factors
- Revenue remains highly dependent on collaboration milestone timing, not recurring
- Cash burn of $105.9M/quarter implies ~5 quarters of runway without additional financing or milestones
- No approved products or near-term registration path for any internal program
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3339126 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 424B5 | $3.47 $3.58 | ▼ −3.32% | ▼ −3.23% | $3.80 (−9.67%) |
Oct 15, 2026 11d ago | 8-K | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $3.80 (−8.65%) |
Oct 15, 2026 11d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $3.80 (−8.65%) |
Oct 15, 2026 11d ago | Press Release | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $3.80 (+8.65%) |
Oct 15, 2026 11d ago | Press Release | $4.16 $3.58 | ▼ −13.94% | ▼ −12.93% | $3.80 (−8.65%) |
Oct 15, 2026 11d ago | 424B5 | $4.16 $3.58 | ▲ +13.94% | ▲ +12.93% | $3.80 (+8.65%) |
Oct 6, 2026 20d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $3.80 (−17.93%) |
Oct 6, 2026 20d ago | 144 | $4.63 $3.84 | ▼ −17.17% | ▼ −17.03% | $3.80 (−17.93%) |
Sep 21, 2026 5w ago | 8-K | $3.97 $3.70 | ▼ −6.80% | ▼ −5.78% | $3.80 (−4.28%) |
Sep 10, 2026 6w ago | Insider Cluster | $3.20 $3.83 | ▲ +19.69% | ▲ +20.03% | $3.80 (+18.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers